Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Baumgärtel

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of General Medicine|May 24, 2019
Mini-review: medication safety of red yeast rice productsAndré Farkouh, Christoph Baumgärtel
Wiener Klinische Wochenschrift|March 7, 2008
[Generic drugs: quality, efficacy, safety and interchangeability]Doris Tschabitscher, Peter Platzer, Christoph Baumgärtel, et al.
Pharmaceutics|October 27, 2022
Interpreting the Benefit and Risk Data in Between-Drug Comparisons: Illustration of the Challenges Using the Example of Mefenamic Acid versus IbuprofenAndré Farkouh, Margit Hemetsberger, Christian R Noe, et al.
Journal of Clinical Medicine|April 30, 2021
Sex-Related Differences in Drugs with Anti-Inflammatory PropertiesAndré Farkouh, Christoph Baumgärtel, Roman Gottardi, et al.
Applied Health Economics and Health Policy|December 25, 2014
Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort studyGeorg Heinze, Milan Hronsky, Berthold Reichardt, et al.
Pharmacoepidemiology and Drug Safety|October 16, 2015
Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort studyGeorg Heinze, Lisanne M Jandeck, Milan Hronsky, et al.
Frontiers in Pharmacology|June 25, 2014
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsBrian Godman, Rickard E Malmström, Eduardo Diogene, et al.
BMC Medicine|August 15, 2013
Personalizing health care: feasibility and future implicationsBrian Godman, Alexander E Finlayson, Parneet K Cheema, et al.
Frontiers in Pharmacology|May 30, 2013
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsRickard E Malmström, Brian B Godman, Eduard Diogene, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of General Medicine|May 24, 2019
Mini-review: medication safety of red yeast rice productsAndré Farkouh, Christoph Baumgärtel
Wiener Klinische Wochenschrift|March 7, 2008
[Generic drugs: quality, efficacy, safety and interchangeability]Doris Tschabitscher, Peter Platzer, Christoph Baumgärtel, et al.
Pharmaceutics|October 27, 2022
Interpreting the Benefit and Risk Data in Between-Drug Comparisons: Illustration of the Challenges Using the Example of Mefenamic Acid versus IbuprofenAndré Farkouh, Margit Hemetsberger, Christian R Noe, et al.
Journal of Clinical Medicine|April 30, 2021
Sex-Related Differences in Drugs with Anti-Inflammatory PropertiesAndré Farkouh, Christoph Baumgärtel, Roman Gottardi, et al.
Applied Health Economics and Health Policy|December 25, 2014
Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort studyGeorg Heinze, Milan Hronsky, Berthold Reichardt, et al.
Pharmacoepidemiology and Drug Safety|October 16, 2015
Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort studyGeorg Heinze, Lisanne M Jandeck, Milan Hronsky, et al.
Frontiers in Pharmacology|June 25, 2014
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsBrian Godman, Rickard E Malmström, Eduardo Diogene, et al.
BMC Medicine|August 15, 2013
Personalizing health care: feasibility and future implicationsBrian Godman, Alexander E Finlayson, Parneet K Cheema, et al.
Frontiers in Pharmacology|May 30, 2013
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsRickard E Malmström, Brian B Godman, Eduard Diogene, et al.
Pageof 1